Author Archives: Bruno Quinney

Bacteria in Petri dishes
#Antimicrobial resistance (AMR) #Gram-negative bacteria #GSK

GSK and Fleming Initiative launch programmes to tackle AMR 

GSK and the Fleming Initiative have launched six major new research programmes aiming to combat antimicrobial resistance (AMR).  The six ‘Grand Challenges’ will bring together scientific expertise and the latest technologies, including AI, to find new ways to slow the progress of AMR. The project has been backed by… Read More

#News

UK
#Cancer research #Nuclear medicine #UK government

UK set to transform nuclear materials into cancer therapies 

Nuclear materials recycled in the UK are set to be used to develop cutting-edge cancer treatments.  A new government-backed project, led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), will use a radionuclide called lead-212 to create treatments known as Targeted Alpha Therapies. The project has… Read More

#Cancer Research #News

Gut microbiome
#Bacteria #Gut microbiome #Immune system

Medication detrimental to gut microbiome, research finds  

The effect of common medication on the gut microbiome could have a detrimental impact on metabolism, the immune system and overall health, a new study reveals.  According to a new paper published in Cell Press, researchers at Stanford University, US, found that medications reduce certain bacterial populations and change… Read More

#News

Blood cells
#CHMP #EMA

Von Willebrand disease drug gets EMA positive opinion 

The European Medicine Agency (EMA) has issued a positive opinion to support the approval of Veyvondi (vonicog alfa) to treat haemorrhages in children with von Willebrand disease (VWD).  Veyvondi has been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The CHMP issued the opinion for treatment of VWD… Read More

#News #Regulatory

#ABPI #ALS #Animal models #Cancer research #Covid-19 #Investment #Life sciences #MHRA #MND #mRNA-based vaccines

DDW Highlights: 18 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, groundbreaking research showed the Covid-19 mRNA vaccine could boost cancer response. Elsewhere,… Read More

#Podcasts

Deal making concept
#Biomarkers #Biotechnology #Drug development

Mursla Bio partners with pharma company on drug development 

Biotechnology company Mursla Bio has announced a partnership with a pharma company to advance biomarker-guided drug development.  While the company has not been named, Mursla Bio says it is a global pharma leader recognised for its expertise in biomarker-guided precision medicine in metabolic dysfunction-associated steatohepatitis (MASH).  Under the collaboration, Mursla… Read More

#Business & Investment #News

Brain physiology
#Alzheimer's #Investment #Neurodegenerative disorders

Scripta raises $12 million to find disease-modifying drugs 

UK techbio company Scripta Therapeutics has announced it has raised $12 million to find disease-modifying drugs altering transcription factor activity.  The financing round was led by by Oxford Science Enterprises and Apollo Health Ventures, with AlbionVC, YZR Capital, and Parkwalk Advisors, with support from Oxford University Innovation.  Scripta’s approach combines… Read More

#Business & Investment #News

Diffuse large B-cell lymphoma
#CAR T-cell therapy #FDA #Lymphoma

FDA grants RMAT designation to T-cell lymphoma candidate 

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to MB-105, a CAR-T cell therapy developed by biotechnology company March Biosciences.  The designation was granted based on data from March Bio’s ongoing multi-centre Phase II clinical trial. Preliminary findings from the safety run-in cohort… Read More

#News #Regulatory

#ABPI #ALS #Animal models #Cancer research #Covid-19 #Investment #Life sciences #MHRA #MND #mRNA-based vaccines

This week in Drug Discovery (10 – 14 November) 

News round-up for 10 – 14 November by Bruno Quinney, Content Team at DDW.  This week’s top story comes from groundbreaking research showing the Covid-19 mRNA vaccine boosts the immune system’s cancer response. The theme of UK investment dominates other headlines, while a report shows an effective… Read More

#News

Patient speaking to psychiatrist
#Clinical trial #Treatment-resistant depression

Positive data announced for treatment-resistant depression drug 

Biopharmaceutical company AtaiBeckley has released positive topline data from the Phase IIb trial of BPL-003 in patients with treatment-resistant depression (TRD).  In the open-label study, BPL-003 met response and remission criteria for depression, with clinically meaningful antidepressant effects sustained up to eight weeks. Patients receiving an 8mg… Read More

#News

Researcher in lab
#Cancer research #CAR-T #Leucid Bio

Leucid Bio establishes proof-of-concept for CAR-T therapy 

Biotechnology company Leucid Bio has established proof-of-concept for CAR-T therapy LEU011 for the treatment of solid tumours.  LEU011 is being evaluated in the ongoing AERIAL trial, but data has established proof-of-concept by demonstrating key biological activity through evidence of encouraging pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Analysis… Read More

#Cancer Research #News

Patient receiving eye drops
#MHRA #Myopia #UK

MHRA approves myopia treatment for children in UK 

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea (low-dose atropine) to slow the progression of myopia in children.  The drug, developed by pharmaceutical company Santen, becomes the first licensed treatment to slow childhood myopia. The approval follows authorisation by the European Commission and the launch in… Read More

#News #Regulatory

Small cell lung cancer
#Cancer therapy #Radiotherapy #Small cell lung cancer

Radiotherapy drug delivers promising early tumour treatment 

New data on Molecular Partners’ radiotherapy candidate MP0712 shows targeted delivery into cancer tumours.  MP0712 is being developed for the treatment of patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. The candidate, which targets DLL3, showed potential to deliver radiotherapy treatment to tumours with… Read More

#Cancer Research #News

Covid-19 vaccination
#Cancer research #Covid-19 vaccine #mRNA-based vaccines

Covid-19 mRNA vaccine boosts cancer response, study shows

Research showing the Covid-19 mRNA vaccine boosts the immune system’s response to cancer has been described as ‘extraordinary’.  Scientists at the University of Florida and the University of Texas MD Anderson Cancer Center found patients with advanced lung or skin cancer lived significantly longer when receiving the… Read More

#Cancer Research #Editor's Choice #News

#Biomedical research #Eli Lilly #Laboratory #Meet the Researcher

Meet the researcher: Catherine Whittington, Associate Professor

DDW’s Diana Turner speaks to Catherine Whittington, Associate Professor in the Department of Biomedical Engineering at WPI, about her current work and the research that drives her.   DT: Can you tell us what you do and what you’re working on at the moment? CW: I teach classes in the biomedical engineering (BME)… Read More

#Exclusive Content #Opinion